Valneva's Pivotal June: Shigella Data and Lyme Vaccine Filing Loom as Shares Hover Above Lows

Valneva shares drop 40% YTD, near 52-week low. Catalysts: Lyme vaccine LB6V (Phase 3 efficacy >70%) and Shigella data expected soon. Revenue guidance cut, restructuring.

Valneva is fighting to regain its footing. The biotech’s stock has shed nearly 40% since the start of the year, closing Friday at €2.33 — a single-day drop of almost 6% that leaves it just 9% above the 52-week floor of €2.13. With the shares trading roughly 38% below their 200-day moving average of €3.74 and an RSI of 38.3 flashing oversold territory, the company is banking on a busy calendar to reignite investor confidence.

June 25 marks the annual general meeting, to be held at the Sofitel Lyon Bellecour. Proxy materials — including the agenda, voting proposals and instructions — have been available on the investor relations page since June 4, and shareholders can request a copy by email up to five days before the event. But the AGM is only one stop on a broader roadshow. Valneva’s management has already appeared at the Jefferies Global Healthcare Conference in New York, the Oddo BHF Nextcap Forum, and the BNP Paribas SMID Cap Conference in Paris. The recurring message: the pipeline, especially the Lyme disease vaccine candidate LB6V.

Developed in partnership with Pfizer, LB6V posted strong Phase 3 results in March 2026 from the VALOR study — more than 70% efficacy against Lyme borreliosis in individuals aged five and older, with no safety concerns. The U.S. FDA has granted fast-track designation, and Pfizer is preparing regulatory submissions. That narrative is real, but it has been overshadowed by commercial headwinds.

Valneva recently trimmed its 2026 revenue guidance for product sales to €135–150 million, down from the earlier range of €145–160 million, citing geopolitical uncertainty that is weighing on demand for travel vaccines. Total revenue, including other income, is still expected to land at €145–160 million. To shore up margins, the company has launched a restructuring drive that aims to cut operating costs by 25% to 35% versus 2025 levels.

On the commercial side, there is a rare bright spot in Brazil. In May, the Brazilian health regulator ANVISA approved local production of Valneva’s chikungunya vaccine IXCHIQ® at the Butantan Institute for adults aged 18 to 59. Inclusion in the public health system could follow. The vaccine contributed to first-quarter product revenue of €30.5 million.

Beyond LB6V, attention is shifting to another pipeline asset: the Shigella candidate S4V2, designed to protect against shigellosis, a leading cause of diarrheal disease and a market estimated at over $500 million annually. Two studies are underway — a Phase 2 trial in infants and a Phase 2b human challenge model. First data are expected in the coming weeks, any day now, making Shigella a potentially binary catalyst alongside the Lyme vaccine filing.

Valneva ended March with cash and equivalents of roughly €105 million (a slightly higher €105.3 million per one disclosure), and raised an additional €37 million through a capital increase in April. The company believes this liquidity will be enough to reach the expected Lyme vaccine approvals. With the AGM on June 25 and Shigella data looming, the month ahead could determine whether the stock’s downward spiral finds a floor or accelerates further.